Skip to main content
DreamCIS INC. logo

DreamCIS INC. — Investor Relations & Filings

Ticker · 223250 ISIN · KR7223250002 KO Professional, scientific and technical activities
Open in API
Filings indexed 197 across all filing types
Latest filing 2026-01-20 Director's Dealing
Country KR South Korea
Listing KO 223250

About DreamCIS INC.

https://dreamcis.com/

DreamCIS INC. is a contract research organization (CRO) that provides comprehensive clinical research services to the pharmaceutical, biotechnology, and medical device industries. The company's offerings cover the full lifecycle of clinical development, including project management, biostatistics, and data management for clinical trials and post-marketing surveillance. DreamCIS specializes in a wide range of therapeutic areas, with extensive experience in oncology, cardiovascular diseases, endocrinology, and rare diseases. In addition to full-service clinical development, the company also provides standalone services, dedicated support for medical device trials, and strategic consulting to guide clients through complex regulatory and development processes.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by executives to disclose changes in their personal shareholdings, specifically due to stock option exercises. This falls under the 'Director's Dealing' category as it reports personal share transactions by a company executive.
2026-01-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their shareholdings and changes therein. In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers personal share transactions and ownership reports by company directors and executives.
2026-01-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 6.1' report) used to disclose insider trading or changes in share ownership by company executives. This aligns perfectly with the 'Director's Dealing' (DIRS) category, which covers personal share transactions by company directors and executives.
2026-01-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and the Korea Exchange. It details changes in share ownership by a major shareholder (HONGKONG TIGERMED CO., LTD) and related parties due to stock option exercises. This type of filing is a standard regulatory requirement for significant ownership changes, which falls under the 'Major Shareholding Notification' category.
2026-01-19 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing from a Korean company (DreamCIS) regarding the exercise of stock options (주식매수선택권행사). It details the number of shares exercised, the exercise price, the individuals involved (directors and employees), and the impact on total outstanding shares. This type of filing is a standard corporate disclosure regarding capital changes resulting from employee/director stock option exercises, which falls under the category of share issues or capital changes.
2026-01-14 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the decision to acquire shares and equity securities of another company (Curi Bio, Inc.). It includes specifics such as the number of shares to be acquired, acquisition price, ownership percentages before and after acquisition, acquisition method, purpose, and scheduled dates. It also provides financial summaries of the target company and related parties, as well as details about the board resolution date and attendance. The content focuses on a capital transaction involving share acquisition and investment, rather than a financial report, management discussion, or regulatory certification. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a simple announcement of a report publication but a substantive disclosure of a capital investment decision. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-11-11 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.